BioPorto A/S (CPH:BIOPOR)
Denmark · Delayed Price · Currency is DKK 1.116
-0.004 (-0.36%)
Nov 6, 2025, 4:54 PM CET
BioPorto Revenue
BioPorto had revenue of 10.59M DKK in the quarter ending June 30, 2025, with 15.12% growth. This brings the company's revenue in the last twelve months to 35.84M, up 5.94% year-over-year. In the year 2024, BioPorto had annual revenue of 36.24M with 17.07% growth.
Revenue (ttm)
35.84M
Revenue Growth
+5.94%
P/S Ratio
14.16
Revenue / Employee
746.67K
Employees
48
Market Cap
507.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 315.60B |
| Coloplast | 27.87B |
| H. Lundbeck | 23.52B |
| Genmab | 23.16B |
| Demant | 22.59B |
| GN Store Nord | 17.33B |
| Zealand Pharma | 9.11B |
| Bavarian Nordic | 6.46B |
BioPorto News
- 2 days ago - Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 - GlobeNewsWire
- 5 weeks ago - BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented - GlobeNewsWire
- 2 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 2 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga
- 3 months ago - BioPorto A/S to host an investor webcast on the results for the first half of 2025 - GlobeNewsWire
- 3 months ago - BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. - GlobeNewsWire
- 5 months ago - BioPorto A/S Announces the Appointment of a New CEO as Part of its Succession Planning Strategy - GlobeNewsWire
- 6 months ago - BioPorto A/S to host first quarter 2025 earnings webcast for investors - GlobeNewsWire